Iclusig (ponatinib) 45mg tablet

Iclusig (ponatinib) is a targeted therapy used in the treatment of certain types of cancer. It is an oral tyrosine kinase inhibitor that specifically targets and blocks the activity of the BCR-ABL protein, which is responsible for driving the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in some patients. Each tablet contains 45 mg of ponatinib, and it is used to treat patients with Philadelphia chromosome-positive (Ph+) leukemia who have not responded to other treatments.

How It Works

Ponatinib, the active ingredient in Iclusig, works by inhibiting the BCR-ABL tyrosine kinase enzyme. This enzyme is produced by the BCR-ABL fusion gene, which is present in most patients with Philadelphia chromosome-positive leukemia. By blocking this enzyme, ponatinib interferes with the signaling pathways that promote cancer cell growth and proliferation. This targeted approach helps to stop the progression of the disease and reduce the number of cancer cells in the body.

Side Effects

Common side effects of Iclusig may include:

• Nausea
• Diarrhea
• Fatigue
• Headache
• Rash
• Muscle pain or joint pain

Serious side effects may include:

• Blood clots or bleeding problems
• Heart problems (e.g., heart attack, heart failure)
• Severe liver problems
• Severe infections
• Pancreatitis
• Severe skin reactions

If any severe side effects occur, contact a healthcare provider immediately.

Indications

Iclusig is indicated for the treatment of:

• Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase, in adult patients who have had prior treatment with other tyrosine kinase inhibitors or are resistant to other treatments.
• Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adult patients with relapsed or refractory disease.

Contraindications

Iclusig is contraindicated in individuals who:

• Have known hypersensitivity to ponatinib or any other component of the formulation.
• Are pregnant or breastfeeding (due to potential harm to the fetus or infant).

Caution is advised for patients with a history of cardiovascular disease, severe liver impairment, or active infections.

Price in Different Countries

Country	Price (per bottle)	References
United States	$18,000 – $22,000 per bottle	GoodRx Iclusig Price
United Kingdom	£13,000 – £16,000 per bottle	NHS Iclusig Price
Australia	$24,000 AUD per bottle	PBS Iclusig Price
India	₹1,40,000 – ₹1,80,000 per bottle	1mg Iclusig Price
Canada	$20,000 – $25,000 CAD per bottle	Canadian Pharmacy Iclusig Price

Top 5 Global Brands for Tyrosine Kinase Inhibitors

The top global brands for tyrosine kinase inhibitors, including those used in the treatment of leukemia, are:

• Imatinib – Brand name: Gleevec (Novartis): One of the first tyrosine kinase inhibitors used in CML treatment.
• Dasatinib – Brand name: Sprycel (Bristol-Myers Squibb): Used for CML and Philadelphia chromosome-positive ALL.
• Nilotinib – Brand name: Tasigna (Novartis): Another option for CML, particularly for patients resistant to imatinib.
• Bosutinib – Brand name: Bosulif (Pfizer): Used for CML in patients who are resistant or intolerant to prior therapies.
• Bruton’s Tyrosine Kinase Inhibitors – Brand name: Imbruvica (AbbVie): Used for B-cell malignancies but has a similar mechanism of action.